6 minutes read time
Beta-blockers are widely prescribed in the management of cardiovascular disease, including heart failure and following myocardial infarction. However, their use in patients with asthma requires careful consideration because blockade of β2-adrenergic receptors in the airways may cause bronchoconstriction [1].
Historically, beta-blockers were generally avoided in patients with asthma because of concerns about bronchospasm. Subsequent evidence suggests that respiratory risk varies between agents. Cardioselective β1-blockers generally have a more favourable respiratory safety profile than non-selective agents and may be considered when there is a compelling cardiovascular indication [1][2].
This article examines the mechanisms underlying beta-blocker-associated bronchoconstriction, differences between cardioselective and non-selective agents, patient-related risk factors for asthma exacerbation, and strategies for reducing respiratory risk during prescribing.
Beta-blockers antagonise β-adrenergic receptors and are used in the management of several cardiovascular conditions. Their clinical effects include reducing heart rate, myocardial contractility, and cardiac workload [1].
Beta-blockers can be broadly classified according to their relative β1 versus β2 selectivity.
β1-adrenergic receptors are predominantly expressed in cardiac tissue, where their activation increases heart rate and myocardial contractility. β2-adrenergic receptors are expressed primarily in bronchial smooth muscle, where stimulation promotes bronchodilation [1].
Blocking β2 receptors can therefore impair β2-mediated bronchodilation and increase airway resistance. This is particularly relevant in asthma, where airway hyperresponsiveness and variable airflow limitation are characteristic features of the disease [1][3].
Non-selective agents block both β1 and β2 receptors and therefore have greater potential to provoke bronchoconstriction, whereas cardioselective agents have a greater affinity for β1 receptors at therapeutic doses. The selectivity of cardioselective β1-blockers is dose dependent. Higher doses may reduce β1 selectivity and thus increase β2-receptor blockade [1][3].
Cardioselective β1-blockers include:
- Metoprolol
- Bisoprolol
- Atenolol
- Nebivolol
Non-selective beta-blockers include:
- Propranolol
- Nadolol
- Sotalol
- Carvedilol
- Labetalol
Clinical risk of cardioselective β1-blockers in asthma
Evidence suggests that cardioselective β1-blockers have a more favourable respiratory safety profile in patients with asthma than non-selective agents.
A 2021 literature review by Bennett et al. examined published evidence together with global pharmacovigilance reports. The review found that serious asthma-related adverse events associated with cardioselective β1-blockers were very uncommon and identified no published reports of fatal asthma directly attributable to cardioselective β1-blocker use in published literature [1].
The authors concluded that the available evidence supports the use of cardioselective β1-blockers in patients with asthma when there is a strong clinical indication, while emphasising that treatment should be initiated cautiously and at the lowest effective dose [1].
Global Initiative for Asthma (GINA) 2026 guidelines similarly recommend that beta-blocker treatment in people with asthma should be considered on a case-by-case basis and initiated under close medical supervision by a specialist. They also state that asthma should not be regarded as an absolute contraindication to cardioselective beta-blockers when indicated for acute coronary events, provided that the relative risks and benefits are considered [2].
The evidence therefore supports a risk–benefit approach rather than blanket avoidance, with potential respiratory risks prioritised when the expected clinical benefit is limited and/or alternative therapies are available [1][2].
Patient-related risk factors for asthma exacerbation
The risk associated with beta-blocker therapy should also be considered in the context of the patient’s underlying asthma and other exacerbation risk factors.
Relevant patient-related factors include [2]:
- Poorly controlled asthma
- Previous severe asthma exacerbation
- Poor adherence to asthma treatment
- Smoking or tobacco exposure
- Obesity
- Chronic rhinosinusitis
- Gastro-oesophageal reflux disease
- Exposure to relevant allergens or respiratory irritants
The presence of multiple risk factors may increase the need for careful assessment before introducing a medicine with potential respiratory effects [2].
Beta-blocker-associated respiratory risk can be managed through individualised prescribing and monitoring.
Practical risk-reduction strategies include:
- Assess asthma control and exacerbation risk before initiating therapy, including recent exacerbations, adherence, smoking, and relevant comorbidities [2]
- Consider a cardioselective β1-blocker where beta-blocker therapy is clinically indicated and a non-selective agent is not specifically required [1][2]
- Use the lowest effective dose and titrate cautiously, recognising that β1 selectivity decreases as the dose increases [1][3]
- Initiate treatment under appropriate medical supervision, particularly in patients with asthma and where respiratory risk is a concern [2][3]
- Monitor for worsening respiratory symptoms following initiation or dose escalation [1]
- Optimise underlying asthma management, including adherence, inhaler technique, and an appropriate asthma action plan [2].
Integration with MIMS Clinical Decision Solutions
MIMS Clinical Decision Solutions, through MIMS Integrated, supports identification of medicine-related health risks at the point of prescribing.
The Drug Health Alert module highlights asthma as a relevant health risk associated with beta-blocker use, providing clinical information and actionable recommendations to support appropriate monitoring or modification of therapy.
Conclusion
Beta-blocker therapy in patients with asthma requires consideration of both cardiovascular benefit and respiratory risk.
Where beta-blocker therapy is clinically indicated, careful selection of a cardioselective agent, cautious dose titration, and appropriate monitoring may help minimise respiratory risk [1][2].
MIMS CDS can complement this approach by highlighting relevant health risks at the point of prescribing and providing evidence-based, actionable guidance to support safer treatment decisions.
References
- Bennett M, Chang CL, Tatley M et al. The safety of cardioselective β1-blockers in asthma: literature review and search of global pharmacovigilance safety reports. ERJ Open Res. 2021 Mar 1;7(1):00801-2020. See more
- Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2026 Update. Global Initiative for Asthma; 2026. See more
- Tiotiu A, Novakova P, Kowal K et al. Beta-blockers in asthma: myth and reality. Expert Rev Respir Med. 2019 Sep;13(9):815-822. See more